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Tamoxifen (TAM) is an anti-oestrogen used for treatment
and prevention of human breast cancer, but it is also
related to human endometrial and uterine cancer. The
wing spot test in Drosophila melanogaster was employed to
determine the genotoxic effects of TAM and 4-nitroquino-
line-1-oxide (4-NQO), a carcinogen that produces adducts
similar to TAM±DNA adducts detected in rodent liver and
human liver microsomes. As Drosophila spp. have no
oestrogen receptor, no effects can result in binding of
TAM to a receptor. Chronic treatments with TAM citrate
were performed with 3-day-old larvae of the standard
(ST) and high bioactivation (HB) crosses of the wing spot
test at concentrations of 0.66, 1.66 and 3.33 mM. In addi-
tion, the carcinogen 4-NQO was administered at 2.5 and
5.0 mM. Somatic spots on normal wings from marker-
heterozygous ¯ies and on serrate wings from balancer-
heterozygous ¯ies were scored to determine mutation and
recombination events in somatic cells for each compound.
The results showed genotoxic effects of TAM at 1.66 and
3.33 mM in the ST cross only and without a clear dose±
response effect. This suggests a weak genotoxicity of this
anti-oestrogen. The negative results obtained with TAM in
the HB cross may indicate ef®cient detoxi®cation of the
compound by the increased xenobiotic metabolism present
in this cross. As reported before, 4-NQO showed genotoxic
effects in the ST cross with a clear dose±response effect.
For the ®rst time, we report enhanced effects of this com-
pound in the HB cross. It is concluded that the geno-
toxicity of TAM in the Drosophila wing spot test is
different from that of 4-NQO.
Introduction
Breast cancer is the most common cancer in women, but is also
present in 1% of men. Tamoxifen citrate salt (TAM), a
triphenylethylene type I non-steroid anti-oestrogen [(Z)-1-(p-
dimethylaminoethoxyphenyl)-1,2-diphenyl-1-butene, Figure 1],
is approved for humans that have or are at risk of getting breast
cancer. TAM is a selective oestrogen response modi®er (SERM)
that exerts antagonistic effects in breast cancer cells and
agonistic effects in other tissues, such as endometrium and bone
(White, 1999). It is proposed that this non-steroid and its
reactive intermediates increase the risk of endometrial and
uterine cancer in breast cancer patients receiving TAM therapy
(IARC, 1996). The mechanism for this increase is unclear,
although two plausible hypotheses have been proposed: (i)
TAM has agonistic effects on oestrogen receptors (ERs) which
induces the development of endometrium or uterine tumour
cells; (ii) cancer is caused by TAM±DNA adducts that lead to
mutations in those cells (see Poirier and Schild, 2003). The two
principal routes of TAM metabolism are a-C-hydroxylation of
the ethyl group that produces a-hydroxytamoxifen (a-OHT),
de®ned as group II adducts (Randerath et al., 1994), and
xenobiotic metabolism by cytochrome P450 2D6 (CYP2D6),
which yields detectable levels of 4-OHT in human liver
microsomes (Dehal and Kupfer, 1997; White, 1999), described
as group I adducts (Randerath et al., 1994). The concentrations
of TAM correlate with the in vitro production of 4-OHT (Crewe
et al., 2002). Low TAM and 4-OHT levels signi®cantly
increased CYP3A4 expression (Desai et al., 2002). It has been
demonstrated that CYP3A4 is the only cytochrome responsible
for yielding a-OHT (Boocock et al., 2002) in correlation with
protein and DNA adduct formation (Notley et al., 2002).
CYP2B prevents the production of TAM±DNA adducts
(StiborovaÂ et al., 2002). In a human lymphoblastoid cell line
(MCL-5) with elevated CYP1A1 and transfected human cDNAs
(CYP1A2, CYP2A6, CYP2E1 and CYP3A4), exposure to TAM
increased micronuclei and caused aneuploidy and structural
abnormalities (Styles et al., 1997). It is clear that cytochrome
P450 enzymes play an important role in the genotoxic effects of
TAM.
The a position of a-OHT joins covalently with the exocyclic
amino group of deoxyguanosine in DNA (N2G alkylation) or in
lesser proportion with the amino group of deoxyadenine (N6A
alkylation) leading in vitro to >90% of total TAM±DNA
adducts, which are identical to those detected in the liver of rats
treated with TAM (Osborne et al., 1997). The variability in the
amounts of adducts could represent differences in oxidative
metabolism of TAM and/or cellular sulphotransferases that
convert a-OHT into an activated form that produces adducts
(Shibutani et al., 1998) and/or differences in nucleotide excision
repair (Shibutani et al., 2000). In mammalian cells, being an
anti-oestrogen, TAM binds to steroid receptors and shows
antagonistic or partial agonistic action. Drosophila melano-
gaster does not have a nuclear ER. It has a nuclear steroid
receptor, a heterodimer that includes the ecdysone receptor
(ECR) and the ultraspiracle (USP) receptor, which is homo-
logous to the retinoid X receptor (RXR). Thackray et al. (2000)
demonstrated that in D.melanogaster TAM exerts its antag-
onism in imaginal eye cells only in an oestrogen-responsive
reporter system that uses transgenic ¯ies carrying an ER. They
proved that some co-regulators and basal transcription factors in
Drosophila are homologous to many mammalian signal
proteins. Without the ER reporter system, TAM cannot exert
any effects related to oestrogenic activity in Drosophila assays.
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The carcinogen 4-nitroquinoline-1-oxide (4-NQO) (Figure 1)
is a pluripotent carcinogen and a strong mutagen in standard
short-term assays. This mutagen produces DNA single-strand
breaks and alkali-labile sites by reactive oxygen species (ROS)
in mammalian cells. Xenobiotic metabolism induces alkali-
stable bulky DNA lesions in purines, via oxidative damage
(N2G > C8G > N6A alkylation), two of them similar to bulky
adducts detected with TAM in rat liver cells (Mirzayans et al.,
1999). 4-NQO has been shown to be genotoxic in the standard
(ST) cross of the wing somatic and mutation recombination test
(SMART) in D.melanogaster (Graf et al., 1989; Hayatsu et al.,
1992; Negishi et al., 1994; Batiste-Alentorn et al., 1995; Kaya
et al., 2002), but it has not been assayed in the high
bioactivation (HB) cross of this in vivo test.
Our experiments were performed to determine the muta-
genic and recombinagenic activity of TAM and 4-NQO (as a
positive control) in somatic cells of D.melanogaster, assuming
that the constitutive or regulated xenobiotic metabolism of both
compounds generates or eliminates genotoxic effects. We used
larvae from the ST and HB crosses of the wing spot test (Graf
et al., 1984, 1998). It is based on the loss of somatic
heterozygosity of two recessive wing cell markers by mutation
and recombination. The ST cross is characterized by regulated
CYP450 genes, whereas the HB cross shows a high constitutive
production of these enzymes (FroÈlich and WuÈrgler, 1989; Graf
and van Schaik, 1992). Drosophila melanogaster has been
shown to have cytochrome P450 enzymes similar to those
found in the S9 fraction of mammalian liver (Clark, 1982;
HaÈllstroÈm et al., 1984). Furthermore, Danielson et al. (1997,
1998) have proven that the CYP6 family of D.melanogaster
shows strong regional homologies with the CYP3 family of
vertebrates which, along with the CYP2 family, are responsible
for drug metabolism in vertebrates. Finally, Saner et al. (1996)
and Dunkov et al. (1997) functionally characterized the
CYP6A2 gene of D.melanogaster responsible for xenobiotic
metabolism in HB strains. Possible genotoxicity of TAM in this
in vivo assay would indicate DNA damage unrelated to ER.
The results could help to clear up the controversies about its
carcinogenicity in TAM users. They may also contribute to the
determination of endometrial or uterine tumour risk for
humans, as has been shown previously with the determination
of genotoxicity of tricyclic antidepressants in Drosophila
(van Schaik and Graf, 1991, 1993). For this group of
compounds a positive correlation between genotoxicity in
Drosophila and increased risk for breast cancer was found in
human epidemiological studies (Sharpe et al., 2002).
Materials and methods
Chemicals
Tamoxifen citrate salt (TAM) (CAS no. 54965-24-1, 99% purity), 4-
nitroquinoline-1-oxide (4-NQO) (CAS no. 56-57-5, 97% purity) and N-
nitrosodimethylamine (NDMA) (CAS no. 62-75-9, 99% purity) were
purchased from Sigma (St Louis, MO). TAM and 4-NQO were dissolved in
a 1:1 mixture of 3% Tween-80 (CAS no. 9005-65-6) from Sigma and 3%
ethanol (Merck, Darmstadt, Germany). NDMA was dissolved in distilled water.
The chemical structures of TAM, 4-NQO and NDMA are shown in Figure 1.
Strains and crosses
The wing spot test uses two markers located on the left arm of chromosome 3:
(i) multiple wing hairs (mwh, 3±0.3), a recessive mutation which produces
multiple trichomes per cell instead of the normally unique trichome; (ii) ¯are-3
(¯r3, 3±38.8), a recessive mutation which produces malformed wing hairs that
have the shape of a ¯are. All three mutant alleles of ¯are are recessive zygotic
lethals. However, homozygous cells in the imaginal discs are viable and lead to
mutant wing cells. The ¯r3 allele is kept over a balancer chromosome carrying
multiple inversions [In(3LR)TM3] and a dominant marker which is
homozygous lethal (BdS, Beaded-Serrate, serrate wings). FroÈlich and
WuÈrgler (1989) constructed a strain (ORR) with increased cytochrome P450-
dependent xenobiotic metabolism which facilitates the detection of promuta-
gens. In particular, the level of CYP6A2 is increased in this strain (Saner et al.,
1996). For the ST cross, females of the strain ¯r3/In(3LR)TM3, BdS were mated
with mwh males. For the HB cross, females of the strain ORR [ORR; ¯r3/
In(3LR)TM3, BdS] and mwh males were crossed.
Collection of larvae and larval feeding
From the two crosses, eggs were collected for 8 h in bottles containing a thick
layer of fermenting live baker's yeast supplemented with sucrose at 25°C, 60±
80% humidity and in the dark. Three days later, the larvae (72 6 4 h) were
washed out of the bottles with tap water through a ®ne-meshed stainless steel
strainer (Graf et al., 1998). Chronic feeding (until pupation, ~48 h) was
performed by adding equal batches of larvae to vials with 0.5 g Drosophila
Instant Medium (Carolina Biological Supply, Burlington, NC) plus 2 ml
solution of the test compounds or controls (Graf et al., 1984; Graf and van
Schaik, 1992). TAM was administered at three concentrations (0.66, 1.66 and
3.33 mM). As a positive control for DNA adducts, 4-NQO was tested at 2.5 and
5.0 mM. NDMA (1.0 and 2.0 mM) is a monofunctional alkylating promutagen
that depends on CYP enzymes to exert genotoxicity (RodrõÂguez-Arnaiz et al.,
1996). It is used routinely as a positive control to document the high
bioactivation characteristics of the HB cross (FroÈlich and WuÈrgler, 1989; Graf
and van Schaik, 1992). For all three test compounds, the appropriate negative
controls were run in parallel. All compounds were tested in three independent
experiments and three replicates for each treatment.
Phenotypes obtained in the wing spot test
Approximately 10±12 days after treatment, the emerging adult ¯ies were
collected from the feeding vials and stored in 70% ethanol. The ST and HB
crosses produce two types of progeny which differ phenotypically based on the
BdS marker: (i) MH, marker-heterozygous ¯ies (mwh+/+ ¯r3 or ORR; mwh+/+
¯r3): wild-type wings; (ii) BH, balancer-heterozygous ¯ies (mwh+/TM3, BdS or
ORR; mwh+/TM3, BdS): serrate wings. Wings of both phenotypes and both
sexes from the two crosses were mounted on slides using Faure's solution (30 g
gum arabic, 20 ml glycerol, 50 g chloral hydrate, 50 ml water).
Wing analysis
The dorsal and ventral surfaces of the wings were scored under a microscope at
4003 magni®cation for the occurrence of small single spots, large single spots
and twin spots (Graf et al., 1984). Single spots are due to mutational or
recombinational events, while twin spots are produced by somatic
recombination only. The sizes of the mwh clones are given as mean size
class, whereby class 1 represents the smallest clone size possible, i.e. class 1
corresponds to 1 cell, class 2 to 2 cells, class 3 to 3±4 cells, class 4 to 5±8 cells,
etc. Hence, the size class represents the number of cell division cycles that
occurred between the time of induction of the clone in the larval imaginal disk
cells and the beginning of differentiation of the wing (Graf et al., 1984). In
order to evaluate the contribution of mitotic recombination events to total
genotoxicity, the frequencies of mwh clones per ¯y were scored in both
phenotypes (MH and BH). In the BH genotype, recombination is suppressed
Fig. 1. Chemical structures of (A) tamoxifen citrate salt (TAM),
(B) 4-nitroquinoline-1-oxide (4-NQO) and (C) N-nitrosodimethylamine
(NDMA).
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due to the inversion-heterozygosity; no twin spots are observed. A comparison
of the frequencies of mwh clones obtained in the MH and BH phenotypes gives
a measure of the relative recombinagenic activity of a compound (RodrõÂguez-
Arnaiz et al., 1996; SpanoÂ et al., 2001).
Data evaluation and statistical analysis
For the statistical assessment of genotoxicity, the frequencies of each type of
spot per ¯y were compared pairwise with the corresponding solvent or water
control. To resolve inconclusive and weak results obtained with the standard
computer program SMART (Frei and WuÈrgler, 1988), we used the special
SMART software (Frei and WuÈrgler, 1995) based on the non-parametric U-test
of Mann, Whitney and Wilcoxon (a = b = 0.05, one-sided).
Results and discussion
The results obtained in the three independent experiments with
the wing SMART with TAM, 4-NQO and NDMA are given in
Table I. Since no statistical differences were found between the
results of individual experiments, the data obtained for both
phenotypes of the two crosses were pooled. The wings of a
total of 1820 ¯ies were analysed in this study. The numbers of
mwh clones and their mean size class as well as the mwh clone
formation frequencies per 105 cells per cell division (Frei and
WuÈrgler, 1995) are also shown in Table I. The size distribu-
tions of the mwh clones recorded after chronic feeding with
TAM and 4-NQO are plotted in Figure 2.
TAM
In the ST cross, TAM gave statistically signi®cant positive
results for the frequencies of total spots per ¯y at the two higher
concentrations in the MH phenotype and at the highest
concentration in the BH phenotype (Table I). The size
distributions of the mwh clones show that in the MH wings,
the frequencies of large single spots are signi®cantly increased,
while in the BH wings this is the case for the small single spots
(see also Figure 2). It is a well-known phenomenon that the
sizes of the mwh clones in BH wings are always smaller than
those in MH wings, which may be due to clones with induced
segmental aneuploidy that show reduced proliferation capacity
(Frei et al., 1992; Frei and WuÈrgler, 1996). This is best
demonstrated here by the values of the mean mwh clone size
class (Table I). This observation is in agreement with Styles
et al. (1997), who reported that TAM is an aneugenic
compound.
Because D.melanogaster has no ER, DNA damage cannot be
produced by any pathway related to this receptor. The
lipophilicity characteristics of TAM and its metabolites
indicate that they can diffuse inside the cell and reach the
nuclear chromatin (El-Kattan et al., 2001). The absence of a
nuclear ER then suggests that the weak genotoxicity of TAM in
the ST cross is the result of DNA adducts. However, the
genotoxic effects observed in the MH wings show no clear
concentration response and only a very weak one in the BH
wings. For this reason, it is not possible to determine in this
cross the contribution of recombinational events to total
genotoxicity in a quantitative way. From the nearly identical
frequencies of mwh clones at the highest concentration in the
two phenotypes it can be concluded that TAM most probably
has mainly mutagenic activity. This conclusion is further
supported by the fact that no positive results were obtained for
the induction of twin spots (Table I), which are exclusively due
to mitotic recombination.
In contrast to these positive results in the ST cross, TAM was
clearly negative in both phenotypes of the HB cross (Table I
and Figure 2). We expected that a-hydroxylation of the ethyl
group of TAM produced by cytochrome P450 enzymes would
lead to more spots in the HB cross. The negative results
obtained in this cross may be explained by an ef®cient
elimination of reactive intermediates by the constitutively
enhanced xenobiotic metabolism in this cross. Similar effects
were demonstrated in mouse liver cells (Moorthy et al., 1997).
Thus, it would seem plausible that group II adducts of TAM
(a-OHT) cause the weak mutagenicity observed in the ST
cross.
The data given in Table I show that a signi®cantly lower
frequency of small single spots was observed with 0.66 mM
TAM in the MH wings of the ST cross compared with the
corresponding negative control frequency. In a similar fashion,
signi®cantly reduced frequencies of large single spots were
observed with 1.66 and 3.33 mM TAM in the MH wings of the
HB cross. This might indicate a possible anti-genotoxic activity
of TAM against spontaneous genetic events, but it may also be
due to chance variation. It might be possible that other effects
of TAM, such as inhibition of oxidative stress by low doses
(Bhimani et al., 1993) or by regulation of xenobiotic metabol-
ism (Moorthy et al., 1997), could cause this decrease. Further
studies with well-known genotoxic agents in combined treat-
ments are needed to demonstrate true anti-genotoxic properties
of small doses of TAM.
4-NQO
As shown in previous studies with the wing spot test, chronic
treatments with 4-NQO gave statistically signi®cant results in
the ST cross for all three types of spots, with a clear dose±
response effect (Graf et al., 1989; Hayatsu et al., 1992; Negishi
et al., 1994; Batiste-Alentorn et al., 1995; Kaya et al., 2002). In
particular, the frequencies of twin spots were also signi®cantly
increased, which indicates recombinagenic activity. Positive
results were also obtained with the HB cross for all three types
of spots (Table I and Figure 2). However, with this cross the
genotoxic effects were considerably higher than with the ST
cross, which is here reported for the ®rst time. The frequencies
of total spots per ¯y in MH wings induced by 2.5 and 5.0 mM
4-NQO are ~1.7-fold higher in the HB cross than in the ST
cross. This increase in genotoxicity is due to the high
constitutive levels of cytochrome P450 enzymes in the HB
cross (Saner et al., 1996). In addition, it is quite evident that
4-NQO is far more genotoxic than TAM (Figure 2).
Furthermore, linear regression analysis of the effects observed
in the two phenotypes of both crosses (data not shown)
indicates that 4-NQO has a high recombinagenic activity in the
HB cross (~73% recombination). Theoretically, 4-NQO gener-
ates ROS that can directly produce DNA single-strand breaks
and alkali-labile sites in a similar manner to ionizing radiation.
Xenobiotic metabolism of 4-NQO produces the metabolite
acetoxyaminoquinoline, which leads to three purine adducts,
like UV light lesions that are repaired by excision repair
(Mirzayans et al., 1999). Direct damage by oxidative stress
would mainly produce mutation events in both crosses. DNA
adducts produced by xenobiotic metabolism could induce
repair activities that may increase recombinational events.
Thus, our results indicate that 4-NQO is a mutagenic but also
recombinagenic compound that is dependent on metabolism by
cytochrome P450 enzymes.
NDMA
The positive control NDMA produced total spot frequencies
~3-fold higher in the HB cross than in the ST cross (Table I). It
gave more small single spots than large single spots, but also
signi®cant frequencies of twin spots as shown previously by
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Kawai (1998) and RodrõÂguez-Arnaiz et al. (1996). These
frequencies were considerably higher than those observed with
4-NQO. As expected, the genotoxicity of NDMA was higher in
the HB cross than in the ST cross. However, the compound was
also de®nitively more toxic in the HB cross so that only very
few ¯ies could be analysed. Regression analysis for the two
phenotypes of the ST cross (data not shown) leads to a value of
36% recombinagenicity, which is lower than the 67% value
observed previously by RodrõÂguez-Arnaiz et al. (1996). It is
most probable that differences in concentrations used and
sample size (Frei and WuÈrgler, 1995) are responsible for this
discrepancy.
General conclusions
Our results indicate that TAM is a weak mutagen in the wing
spot test of Drosophila. It is suggested that xenobiotic
metabolism (Moorthy et al., 1997) in the HB cross with high
levels of cytochromes P450 decreases group II DNA adducts in
such a way that this compound and its metabolites were not
genotoxic in this cross. The weak genotoxicity of TAM was
thus con®rmed in this eukaryotic in vivo assay. In order to
interpret these results, we must also consider that Drosophila
has been shown to have some co-regulators and basal
transcription factors homologous to human metabolism of
TAM (Thackray et al., 2000). Furthermore, there are strong
homologies between the CYP6 family of insects and the CYP3
family of vertebrates (Danielson, 1997, 1998), and CYP3A4
yields a-OHT (Boocock et al., 2002). The difference in the
regulated and high constitutive synthesis of CYP450 enzymes
in the ST and HB crosses, respectively, could result in a high
ability to metabolize TAM and thus avoid DNA damage in the
HB cross but not in the ST cross. These quantitative enzymatic
differences between the two crosses which produce different
genotoxicity results resemble other data obtained with human
and rat tissues or organs exposed to TAM (Poirier and Schild,
2003). In humans, 4-OHT metabolism is by a thermostable
sulphotransferase. This polymorphic enzyme has a wild-type
allele SULT1A1*1 and an altered allele SULT1A1*2, with
~40% activity. Poirier and Schild (2003) speculated that TAM
detoxi®cation accomplished by SULT1A1 reduces the con-
centration of drug available for genotoxic activation.
Therefore, the less ef®cient SULT1A1*2 could increase
Fig. 2. Distribution of the mwh clone sizes after feeding of larvae of the ST and the HB cross (MH and BH wings) with different concentrations (mM) of TAM
and 4-NQO (TW, Tween±ethanol 3%). The clone sizes are 1, 2, 3±4, 5±8, 9±16, 17±32 and >32 cells.
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genotoxic activation. Phillips (see Poirier and Schild, 2003)
suggested that the presence of another sulphotransferase
SULT2A1, an enzyme found only in rat hepatocytes exposed
to TAM and a-OHT, is related to TAM±DNA adduct
detection. On the other hand, the absence of SULT2A1 in
other cells and tissues of rat and human (lymphocytes and
endometrium, respectively) is related to a lack of TAM±DNA
adducts. This evidence supports the idea that enzymatic
differences may be responsible for the presence or absence of
TAM±DNA adducts. We conclude that our study in Drosophila
supports the hypothesis that the magnitude of genotoxicity of
TAM may be related to quantitative enzymatic differences.
Furthermore, our results indicate that the genotoxicity of
TAM differs from that of 4-NQO because the latter
possesses signi®cant recombinagenic activity and shows a
high bioactivation effect.
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